Search

Your search keyword '"Beşışık, Fatih"' showing total 86 results
Start Over Author "Beşışık, Fatih"
86 results on '"Beşışık, Fatih"'

1. WED-318-YI Steatotic liver disease in diabetic patients: more serious diabetes mellitus, more serious liver disease

Author

İstemihan, Zülal, primary, Bektaş, Fatih, additional, Bardak, Ali Emre, additional, Kızıltaş, Cansu, additional, Kemeç, Gamze, additional, Nuriyev, Kanan, additional, Rüstemzade, Aynure, additional, Uluçeçen, Sezen Genç, additional, Hacışahinoğulları, Hülya, additional, Karşıdağ, Kubilay, additional, Çavuş, Bilger, additional, Örmeci, Asli Çifcibasi, additional, Akyuz, Filiz, additional, Demir, Kadir, additional, Beşışık, Fatih, additional, and Kaymakoğlu, Sabahattin, additional

Published
2024
Full Text
View/download PDF

4. Enhancing Diagnostic Yield of EUS-Guided FNA Through On-site Cytopathology.

Author

Günay, Deniz Sevindik, Çavuş, Bilger, Örmeci, Aslı Çifçibaşı, Şahin, Davut, Demir, Kadir, Beşışık, Fatih, Kaymakoğlu, Sabahattin, and Akyüz2, Filiz

Subjects
CELLULAR pathology, ENDOSCOPIC ultrasonography, MEDICAL personnel, MEDICAL screening, MEDICAL care
Abstract

Objective: The diagnostic yield of endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA) can vary according to many factors. We aimed to determine the predictors that optimize the diagnostic yield of EUS-FNA, particularly the role of on-site cytopathologists. Methods: A total of 175 patients who underwent EUS-FNA were retrospectively enrolled in this study. Lesion localization, size, characteristics, and the presence of a cytopathologist during the examination were evaluated. A standard endoscope and a Cook Medical Echo Tip 22G needle were used to view, evaluate, and perform FNA on the lesions using the Standard Suction Technique. Results: The most common lesion location was the pancreas, accounting for 70% of cases. The average lesion size was 3.2 ± 1.7 cm. Rapid on-site pathological evaluations (ROSE) were performed for 64 patients (37%), significantly improving diagnostic rates to 78% compared to 63% without ROSE (OR 2.09, 95% CI 1-4.2, P = .039). The diagnostic yield was higher for solid lesions compared to cystic ones (OR 2.2, 95% CI 1-4.7, P = .03). A positive correlation was found between lesion size and diagnostic yield (R 0.18, P = .017). ROC analysis showed that lesions larger than 2.4 cm had a diagnostic specificity of 73% and sensitivity of 45% (AUC 0.61, P = .019). Conclusion: Our findings clearly revealed that ROSE enhances the diagnostic yield and procedural efficiency of EUS-FNA. This may be related to the high quality of smears prepared by the cytopathologist. Furthermore, larger lesion sizes were associated with higher diagnostic accuracy, particularly in pancreatic lesions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational Study

Author

Artan, Ayşe Serra, primary, Mirioğlu, Şafak, additional, İstemihan, Zulal, additional, Aksoy, Elif, additional, Dirim, Ahmet Burak, additional, Çavuş, Bilger, additional, Oto, Özgür Akın, additional, Çifçibaşı-Örmeci, Aslı, additional, Beşışık, Fatih, additional, Çalışkan, Yaşar, additional, Öztürk, Savaş, additional, Yazıcı, Halil, additional, Kaymakoğlu, Sabahattin, additional, and Türkmen, Aydın, additional

Published
2023
Full Text
View/download PDF

13. Evaluation of safety and efficacy of tenofovir disoproxil in hemodialysis and renal transplant patients monoinfected with hepatitis B virus based on real life data

Author

Akyüz, Filiz, primary, Çavuş, Bilger, additional, Nizam, Nihan, additional, Göktürk, Suut, additional, Baran, Bülent, additional, Yazıcı, Halil, additional, Evirgen, Sami, additional, Akyüz, Ümit, additional, Öbekli, Tuba, additional, Karaca, Çetin, additional, Demir, Kadir, additional, Beşışık, Fatih, additional, and Kaymakoğlu, Sabahattin, additional

Published
2022
Full Text
View/download PDF

17. Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience

Author

Değertekin, Bülent, Demir, Mehmet, Akarca, Ulus S., Kani, Haluk Tarık, Uçbilek, Enver, Yıldırım, Emre, Güzelbulut, Fatih, Balkan, Ayhan, Vatansever, Sezgin, Danış, Nilay, Demircan, Melek, Soylu, Aliye, Yaras, Serkan, Kartal, Aysun, Kefeli, Ayşe, Gündüz, Feyza, Yalçın, Kendal, Erarslan, Elife, Aladag, Murat, Harputluoğlu, Murat, Özakyol, Aysegül, Temel, Tuncer, Akarsu, Mesut, Sümer, Hale, Akın, Mete, Albayrak, Bülent, Şen, İlker, Alkım, Hüseyin, Uyanıkoğlu, Ahmet, Irak, Kader, Öztaşkın, Sinem, Uğurlu, Çağrı Burak, Günes, Şevkican, Gürel, Selim, Nuriyev, Kenan, İnci, İsmail, Kaçar, Sabite, Dinçer, Dinç, Doğanay, Levent, Göktürk, Hüseyin Savaş, Mert, Ali, Coşar, Arif Mansur, Dursun, Hakan, Atalay, Roni, Akbulut, Sabiye, Balkan, Yasemin, Köklü, Hayrettin, Şimsek, Halis, Özdoğan, Osman, Çoban, Mehmet, Poturoğlu, Şule, Ayyıldız, Talat, Yapalı, Suna, Günsar, Fulya, Akdoğan, Meral, Özenirler, Seren, Akyıldız, Murat, Sezgin, Orhan, Kaymakoğlu, Sabahattin, Beşışık, Fatih, Karasu, Zeki, İdilman, Ramazan, Dicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalı, Gastroenteroloji & Hepatoloji Bölümü, Yalçın, Kendal, Dicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç HastalıklarAna Bilim Dalı, Degertekin B., Demir M., Akarca U. S., KANİ H. T., Ucbilek E., Yildirim E., Guzelbulut F., Balkan A., Vatansever S., DANIŞ N., et al., Acibadem University Dspace, and Ege Üniversitesi

Subjects
Internal Diseases, Cyclopropanes, Male, Sofosbuvir, Turkey, medicine.medical_treatment, Hepacivirus, Liver transplantation, Sağlık Bilimleri, Direct-acting antiviral, medicine.disease_cause, Gastroenterology, İç Hastalıkları, Clinical Medicine (MED), chemistry.chemical_compound, Liver disease, 0302 clinical medicine, HEPATOCELLULAR-CARCINOMA, INFECTION, Klinik Tıp (MED), Anilides, 030212 general & internal medicine, Prospective Studies, CIRRHOSIS, Sulfonamides, Klinik Tıp, biology, Original Article: Liver, Valine, Middle Aged, GASTROENTEROLOJİ VE HEPATOLOJİ, Tıp, Hepatoloji, Treatment Outcome, SUSTAINED VIROLOGICAL RESPONSE, HCV, Medicine, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Female, RIBAVIRIN, medicine.drug, Ledipasvir, medicine.medical_specialty, Proline, Hepatitis C virus, Lactams, Macrocyclic, Direct-Acting Antiviral, Gastroenterology and Hepatology, Antiviral Agents, ACTING ANTIVIRAL THERAPY, 03 medical and health sciences, Gastroenteroloji-(Hepatoloji), Internal medicine, Health Sciences, medicine, Humans, Aged, Retrospective Studies, Fluorenes, Internal Medicine Sciences, Ritonavir, Hepatology, business.industry, GASTROENTEROLOGY & HEPATOLOGY, Dahili Tıp Bilimleri, CLINICAL MEDICINE, Hepatitis C, Chronic, medicine.disease, Gastroenteroloji, Treatment, chemistry, Alanine transaminase, Paritaprevir, biology.protein, Benzimidazoles, Liver function, business
Abstract

Background/Aims: This study aimed to evaluate the real-life efficacy and tolerability of direct-acting antiviral treatments for patients with chronic hepatitis C (CHC) with/without cirrhosis in the Turkish population. Material and Methods: A total of 4,352 patients with CHC from 36 different institutions in Turkey were enrolled. They received ledipasvir (LDV) and sofosbuvir (SOF)+/- ribavirin (RBV) ombitasvir/paritaprevir/ritonavir +/- dasabuvir (PrOD)+/- RBV for 12 or 24 weeks. Sustained virologic response (SVR) rates, factors affecting SVR, safety profile, and hepatocellular cancer (HCC) occurrence were analyzed. Results: SVR12 was achieved in 92.8% of the patients (4,040/4,352) according to intention-to-treat and in 98.3% of the patients (4,040/4,108) according to per-protocol analysis. The SVR12 rates were similar between the treatment regimens (97.2%-100%) and genotypes (95.6%-100%). Patients achieving SVR showed a significant decrease in the mean serum alanine transaminase (ALT) levels (50.90 +/- 54.60 U/L to 17.00 +/- 14.50 U/L) and model for end-stage liver disease (MELD) scores (7.51 +/- 4.54 to 7.32 +/- 3.40) (p, Turkish Association for the Study of The Liver (TASL), The present study was supported by The Turkish Association for the Study of The Liver (TASL).

Published
2020

19. SAT-485 - The liver worsens in non-alcoholic fatty liver disease patients as diabetes mellitus worsens and lasts longer

Author

İstemihan, Zülal, Bektaş, Fatih, Bardak, Ali Emre, Kızıltaş, Cansu, Kemeç, Gamze, Imanov, Ziya, Senkal, Volkan, Nuriyev, Kanan, Rüstemzade, Aynure, Genç, Sezen, Hacışahinoğulları, Hülya, Karşıdağ, Kubilay, Çavuş, Bilger, Örmeci, Aslı Çifcibaşı, Akyuz, Filiz, Demir, Kadir, Besisik, Fatih, and Kaymakoglu, Sabahattin

Published
2023
Full Text
View/download PDF

27. Risk factors associated with progression to intestinal complications of Crohn disease

Author

Baran, Bülent (ORCID 0000-0001-7966-2346 & YÖK ID 167583), Kayar, Yusuf; Örmeci, Aslı Çiftçibaşı; Akyuz, Filiz; Demir, Kadir; Beşışık, Fatih; Kaymakoğlu, Sabahattin, School of Medicine, Department of Internal Diseases, Gastroenterology and Hepatology, Baran, Bülent (ORCID 0000-0001-7966-2346 & YÖK ID 167583), Kayar, Yusuf; Örmeci, Aslı Çiftçibaşı; Akyuz, Filiz; Demir, Kadir; Beşışık, Fatih; Kaymakoğlu, Sabahattin, School of Medicine, and Department of Internal Diseases, Gastroenterology and Hepatology

Abstract

Background: crohn disease is a chronic bowel disease that causes serious complications. Prevalence of Crohn disease is increasing. Studies have shown that the behavior of the disease is not stable and severe complications secondary to behavior change over time have been shown. In this study, we aimed to evaluate the prognostic risk factors associated with phenotypic change in Crohn disease in a Turkish patient cohort. Methods: patients followed up from March 1986 to August 2011 were evaluated for demographic and clinical characteristics to determine possible risk factors and initial clinical phenotype of the disease based on the Montreal classification. The cumulative probabilities of developing stricturing or penetrating intestinal complications were estimated using the Kaplan-Meier analysis. Univariate and multivariate Cox-proportional hazard models were used to assess associations between baseline clinical characteristics and intestinal complications. Results: three hundred and thirty patients (mean age, 30.6 ± 11.1 years; 148 female) were included in the study. Mean follow-up duration was 7.4 ± 5.3 years (range: 1.0-25.0 years). At baseline 273 patients had inflammatory-type disease, 57 patients experienced stricturing/penetrating intestinal complications before or at the time of diagnosis. The cumulative probability of developing complicated disease was 37.4% at 5 years, 54.3% at 10 years, 78.8% at 25 years. Independent predictors associated with progression to intestinal complications were current smoking, perianal disease, extra-intestinal manifestations, and location of disease. Conclusions: location of disease is the most powerful indicator for the development of stenosis and penetrating complications in inflammatory-type disease. Patients with ileal involvement should be considered for more aggressive immunosuppressive therapy., NA

Published
2019

28. Predicting mortality in patients with spontaneous bacterial peritonitis using routine inflammatory and biochemical markers

Author

Baran, Bülent (ORCID 0000-0001-7966-2346 & YÖK ID 167583), Iliaz, Raim; Özpolat, Tahsin; Demir, Kadir; Kaymakoğlu, Sabahattin; Beşışık, Fatih; Akyüz, Filiz, Koç University Hospital, Baran, Bülent (ORCID 0000-0001-7966-2346 & YÖK ID 167583), Iliaz, Raim; Özpolat, Tahsin; Demir, Kadir; Kaymakoğlu, Sabahattin; Beşışık, Fatih; Akyüz, Filiz, and Koç University Hospital

Abstract

Objectives: Spontaneous bacterial peritonitis (SBP) is a common and high-mortality infectious complication of patients with cirrhosis. New inflammatory markers are associated with morbidity/mortality in various diseases. The aim of our study was to find the 30-day mortality rate of SBP and their predictors. Patients and methods: Seventy patients with cirrhosis complicated with SBP and 55 non-SBP controls were enrolled into the study, and patients were evaluated for mortality rate and its predictors. Results: The 30-day and 3-month mortality rates in the SBP group were 26.1 and 50.7%, respectively. Mortality rates were higher in the SBP group than in the controls. Symptoms at hospital admission and cell counts in ascitic fluid made no difference in predicting 30-day mortality. Patients with SBP with high serum neutrophil counts, high neutrophil-lymphocyte ratio, high C reactive protein (CRP)/albumin ratio, and high model for end-stage liver disease (MELD) score had higher 30-day mortality rates. We determined optimal cutoff values of MELD scores and serum neutrophil counts for predicting 30-day mortality as 20.5 and 6850/mm(3), respectively. The sensitivity and specificity for the MELD cutoff value were 83.3 and 80.4%, respectively. We also followed up patients for 60 months after SBP; the patients with high inflammatory markers and MELD scores at the time of SBP diagnosis had worse survival compared with the group with lower levels. Conclusion: Our results suggest that SBP has high 30-day mortality. MELD scores and inflammatory markers (CRP, CRP albumin ratio, neutrophil-lymphocyte ratio) may be used to predict mortality in patients with SBP., NA

Published
2018

30. İnflamatuvar barsak hastalığının ekstraintestinal tutulumu

Author

Uyanıkoğlu, Ahmet, Akyüz, Filiz, Ermiş, Fatih, Demir, Kadir, Özdil, Sadakat, Beşışık, Fatih, and Mungan, Zeynel

Subjects
Gastroenteroloji ve Hepatoloji
Abstract

Giriş ve Amaç: İnflamatuvar barsak hastalığında ekstraintestinal bulgu - ların sıklığı %6-47 olarak bildirilmiştir. Kliniğimizde takip edilen inflama- tuvar barsak hastalarında görülen ekstraintestinal bulguları değerlendir- dik. Gereç ve Yöntem: Nisan 1998 ve Ocak 2008 arasında takip edilen hastalar ekstraintestinal bulgular, epidemiyolojik veriler, hastalık sürele- ri, komplikasyonları açısından retrospektif olarak değerlendirildi. Bulgu- lar: 494 hasta (254 erkek, yaş ortalaması 38,6313,32 yıl, yaş dağılımı 6-78) değerlendirmeye alındı. Bu hastalardan 283ü (%57,3) ülseratif kolit, 194ü (%39,3) Crohn hastalığı ve 17si (%3.4) indetermine kolit idi. Hastalık yaşı ortalama 70,6675,93 (1-1008) ay idi. Ortalama takip süresi 36,4045,09 ay (1-288 ay) idi. Tüm inflamatuvar barsak hastala- rında ekstraintestinal bulguların sıklığı %19,2 (95/494) olup dağılımı: seronegatif artrit 32 (%6,5), hepatik tutulum 13 (%2,6), deri tutulumu 3 (%2,6), kombine 16 (%3,2), renal kalkül 12 (%2,4), tromboemboli 5 (%1), göz tutulumu 4 (%0,8) idi. 78 hastada (%15,8) komplikasyon görüldü: [29 abse (%5,9), 15 perforasyon (%3), 5 malignite (%1), 1 toksik megakolon (%0,2) ve 15 diğer komplikasyonlar (%2,6)]. Crohn hastalığında komplikasyon oranı ülseratif kolitten fazla idi (%29,3e %3,6). Ülseratif kolitli hastalarda ekstraintestinal bulgular ile kompli- kasyon sıklığı arasında (p0,007, R0,173), Crohn hastalarında kolonik tutulum ile ekstraintestinal bulgular arasında (p0,04, R0,144) pozitif korelasyon tesbit edildi. Sonuç: İnflamatuvar barsak hastalarında en sık ekstraintestinal bulgu seronegatif artrittir. En sık komplikasyon ise abse ve perforasyondur. Ekstraintestinal bulguların varlığı ülseratif kolit seyrinde komplikasyon riskini arttırır. Crohn hastalığında kolonik tutu - lum, ekstraintestinal bulguların varlığını gösteren prediktif bir faktördür. Background and Aims: The reported frequency of extraintestinal manifestations in inflammatory bowel disease varies from 6% to 47%. We evaluated extraintestinal manifestations of inflammatory bowel disease patients who were followed up in our clinic. Materials and Methods: The epidemiological findings, disease duration, extraint- estinal manifestations, and complications were evaluated between April 1998 and April 2008, retrospectively. Results: Four hundred and ninety-four patients (254 males; mean age, 38,63±13,32 years; range, 16-78) were evaluated: 283 (57,3%) with ulcerative colitis, 194 (39,3%) with Crohns disease and 17 (3.4%) with indeterminate colitis. The mean disease duration was 70,66±75,93 months (1-1008 months), and the mean follow-up was 36,40±45,09 months (1-288 months). The extraintestinal manifestation rate was 19.2% (95/494) in the whole group, and included arthritis in 32 (6,5%), hepatobiliary in 13 (2,6%), skin in 13 (2,6%), multiple extraintestinal manifestations in 16 (3,2%), renal calculus in 12 (2,4%), thromboembolic events in 5 (1%), and eye involvement in 4 (0,8%). Complications were observed in a total of 78 patients (15,8%). Complication rates were as follows: 29 (5,9%) abscess, 15 (3%) perforation, 5 (1%) malignancy, 1 (0,2%) toxic megacolon, and 15 (2,6%) others. The complication rate was higher in Crohns disease than ulcerative colitis (29,3% vs 3,6%). There was a positive correlation between extraintestinal manifestations and the complication rate in ulcerative colitis (p0,007, r0,173), and a positive correlation was observed between colonic involvement and extraintesti- nal manifestations in Crohns disease (p0,04, r0,144). Conclusions: The most common extraintestinal manifestation was arthritis, and the most frequently seen complications were abscess and perforation. The complication rate was higher in Crohns disease than ulcerative colitis. Extraintestinal manifestations may enhance the complication rate in UC. In Crohns disease, the extraintestinal manifestations rate is higher in colonic involvement than in ileocolonic and ileal involvement. Colonic involvement in Crohns disease is a predictive factor for extraintestinal manifestations.

Published
2014

32. Hepatik kitle ile prezente olan, ERCP ile ekstraksiyonu yapılan Fasciola hepatica: olgu sunumu ve literatürün gözden geçirilmesi

Author

Uyanıkoğlu, Ahmet, Demir, Kadir, Akyüz, Filiz, Ermiş, Fatih, Beşışık, Fatih, and Boztaş, Güngör

Subjects
parasitic diseases, Gastroenteroloji ve Hepatoloji
Abstract

Fasciola hepatica infeksiyonu ülkemizin bazı bölgelerinde endemik olarak rastlanan bir karaciğer trematodudur. Klinik bulgular nonspesifik olup; karın ağrısı, sağ üst kadranda hassasiyet şeklinde olabilir. Laboratuvarda eozinofi- li, karaciğer enzimlerinin yükselmesi, pozitif seroloji görülür. Görüntüleme yöntemlerinde karaciğerde çok sayıda nodüller ve safra yollarında dilatasyon görülür. Triclabendazol hepatik ve biliyer fazda etkilidir. Endoskopik retrog- rad kolanjiopankreatografi ile canlı Fasciola hepaticaların biliyer kanaldan uzaklaştırılması ile de tedavi edilir. Burada karaciğerde kitle nedeniyle tetkik edilen, safra yollarında dilatasyona neden olan ve endoskopik retrograd ko- lanjiopankreatografi ile tedavi edilen fasciola hepaticalı genç bayan olgusu sunulmuştur. Fasciola hepatica is a liver trematode that is endemic in some parts of Turkey. Clinical findings are nonspecific, such as abdominal pain and right upper quadrant tenderness. Eosinophilia, elevated liver enzymes and positive se- rology can be detected in laboratory investigations, while multiple nodules in the liver and dilated bile ducts can be seen in imaging modalities. Tricla- bendazole is effective in the hepatic and biliary phases. Fasciola hepatica is also treated with endoscopic retrograde cholangiopancreatography by biliary duct removal. Herein, we present a young woman who was evaluated with a mass in the liver and biliary tract dilatation caused by Fasciola hepatica and who was treated with endoscopic retrograde cholangiopancreatography.

Published
2013

49. Karaciğer amiloidoz depolanmasını göstermede yeni bir non-invazif tanı yöntemi olarak transient elastografi (fibroscan).

Author

Bektaş, Murat, Çavuş, Bilger, Ağargün, Besim Fazıl, Şenkal, Volkan, Koca, Nevzat, İnce, Burak, Mestanzade, Metban, Karaca, Pelin Özer, Büyük, Melek, Yalçınkaya, Yasemin, Esen, Bahar Artım, İnanç, Murat, Güllüoğlu, Mine, Buğra, Zehra, Beşışık, Sevgi, Beşışık, Fatih, and Gül, Ahmet

Abstract

Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results